Drug intelligence / Profile preview

ADB-150

Development stage: Unknown
Lead developer: AdaptBio Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Injection

Overview

ADB-150 is a chimeric peptide vaccine developed by AdaptBio Therapeutics. It is designed as a T-cell and B-cell immunotherapy that targets Programmed Cell Death Protein 1 (PD-1). By eliciting immune responses against PD-1-related epitopes, the vaccine aims to drive anti-tumor immunity. It is currently in Phase 1/1a clinical development for the treatment of non-small cell lung cancer (NSCLC) and microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ADB-150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-150.

Explore the full profile